116 related articles for article (PubMed ID: 3907840)
1. Radionuclide ventriculography for evaluation and prevention of doxorubicin cardiotoxicity.
Steinberg JS; Wasserman AG
Clin Ther; 1985; 7(6):660-7. PubMed ID: 3907840
[TBL] [Abstract][Full Text] [Related]
2. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies.
Carrió I; Lopez-Pousa A; Estorch M; Duncker D; Berná L; Torres G; de Andrés L
J Nucl Med; 1993 Sep; 34(9):1503-7. PubMed ID: 8355070
[TBL] [Abstract][Full Text] [Related]
3. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.
Alexander J; Dainiak N; Berger HJ; Goldman L; Johnstone D; Reduto L; Duffy T; Schwartz P; Gottschalk A; Zaret BL
N Engl J Med; 1979 Feb; 300(6):278-83. PubMed ID: 759880
[TBL] [Abstract][Full Text] [Related]
4. Radionuclide ejection fraction in doxorubicin cardiotoxicity.
Morgan GW; McIlveen BM; Freedman A; Murray IP
Cancer Treat Rep; 1981; 65(7-8):629-38. PubMed ID: 7248982
[TBL] [Abstract][Full Text] [Related]
5. Selective right ventricular dysfunction following doxorubicin therapy.
Sperber AD; Cantor AA; Biran H; Keynan A
Isr J Med Sci; 1987 Aug; 23(8):896-9. PubMed ID: 3679793
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity.
McKillop JH; Bristow MR; Goris ML; Billingham ME; Bockemuehl K
Am Heart J; 1983 Nov; 106(5 Pt 1):1048-56. PubMed ID: 6637763
[TBL] [Abstract][Full Text] [Related]
7. Adriamycin (doxorubicin) cardiotoxicity: a review.
Chlebowski RT
West J Med; 1979 Nov; 131(5):364-8. PubMed ID: 394479
[TBL] [Abstract][Full Text] [Related]
8. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.
Schwartz RG; McKenzie WB; Alexander J; Sager P; D'Souza A; Manatunga A; Schwartz PE; Berger HJ; Setaro J; Surkin L
Am J Med; 1987 Jun; 82(6):1109-18. PubMed ID: 3605130
[TBL] [Abstract][Full Text] [Related]
9. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
10. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation.
Shapira J; Gotfried M; Lishner M; Ravid M
Cancer; 1990 Feb; 65(4):870-3. PubMed ID: 2297656
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era.
Mitani I; Jain D; Joska TM; Burtness B; Zaret BL
J Nucl Cardiol; 2003; 10(2):132-9. PubMed ID: 12673177
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography.
Palmeri ST; Bonow RO; Myers CE; Seipp C; Jenkins J; Green MV; Bacharach SL; Rosenberg SA
Am J Cardiol; 1986 Sep; 58(7):607-13. PubMed ID: 3751931
[TBL] [Abstract][Full Text] [Related]
13. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance.
Choi BW; Berger HJ; Schwartz PE; Alexander J; Wackers FJ; Gottschalk A; Zaret BL
Am Heart J; 1983 Oct; 106(4 Pt 1):638-43. PubMed ID: 6613807
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas.
Dresdale A; Bonow RO; Wesley R; Palmeri ST; Barr L; Mathison D; D'Angelo T; Rosenberg SA
Cancer; 1983 Jul; 52(1):51-60. PubMed ID: 6850545
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive methods for the early detection of doxorubicin-induced cardiomyopathy.
Lenzhofer R; Dudczak R; Gumhold G; Graninger W; Moser K; Spitzy KH
J Cancer Res Clin Oncol; 1983; 106(2):136-42. PubMed ID: 6630284
[TBL] [Abstract][Full Text] [Related]
17. Radionucleotide ejection fraction and prediction of doxorubicin cardiotoxicity.
Morgan GW; Choy D; Freedman A
Lancet; 1978 Jun; 1(8077):1315-6. PubMed ID: 78081
[No Abstract] [Full Text] [Related]
18. Gated blood pool scintigraphic monitoring of doxorubicin cardiomyopathy: comparison of camera and computerized probe results in 101 patients.
Strashun AM; Goldsmith SJ; Horowitz SF
J Am Coll Cardiol; 1986 Nov; 8(5):1082-7. PubMed ID: 3760382
[TBL] [Abstract][Full Text] [Related]
19. Reversible doxorubicin-induced congestive heart failure.
Cohen M; Kronzon I; Lebowitz A
Arch Intern Med; 1982 Aug; 142(8):1570-1. PubMed ID: 7103641
[TBL] [Abstract][Full Text] [Related]
20. Review of tests for monitoring doxorubicin-induced cardiomyopathy.
Ganz WI; Sridhar KS; Ganz SS; Gonzalez R; Chakko S; Serafini A
Oncology; 1996; 53(6):461-70. PubMed ID: 8960141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
